AbbVie, Scripps Research to collaborate on COVID-19 treatments

LabPulse.com staff writers
Mar 14, 2022
2021 08 23 18 25 2180 Covid Treatment Doctor 400

AbbVie and Scripps Research plan to collaborate on developing antiviral treatments for COVID-19.

The initial research program was conducted at Calibr, Scripps Research's drug discovery and development division, and received funding from the Bill & Melinda Gates Foundation.

Latest in Drug Discovery and Development
2019 05 17 20 09 8391 Hpv 400
Enzo launches RNA gene expression platform for HPV
September 25, 2022
2022 09 09 16 29 7140 Computer Head 400
Lunaphore, Nucleai to provide AI-based spatial biology analysis
September 8, 2022
2022 04 05 16 58 0661 Drug Discovery Development Analysis 400
BD, Labcorp to develop flow cytometry CDx
August 8, 2022
2021 08 18 23 12 2135 Computer Ai Artificial Illustration 400
Nucleai, Ultivue to partner on AI-based drug development platform
June 5, 2022
Related Stories
2019 12 09 20 32 9244 Multiple Myeloma 400
Collaboration
AbbVie to acquire TeneoOne
2020 10 19 22 00 1118 Blood Cells 400
Multiple Myeloma
AbbVie gets FDA nod for new use of Venclexta
2019 12 09 20 32 9244 Multiple Myeloma 400
Leukemia
AbbVie to deploy Adaptive's clonoSeq test in myeloma trials
2020 03 11 18 43 2074 Artificial Intelligence Ai Suit 400
Drug Discovery and Development
Precision Medicine Institute to host show on AI and diagnostics
More in Drug Discovery and Development
Enzo launches RNA gene expression platform for HPV
The platform's products combine sequence-specific probes with Enzo's LoopRNA in situ hybridization (ISH) technology, enabling the products to detect target genes in tissue or cell samples while preserving the morphology, Enzo said. This study of single cells within their native tissue environment, called spatial biology, helps scientists characterize and understand disease, Enzo added.
September 25, 2022
2019 05 17 20 09 8391 Hpv 400
Lunaphore, Nucleai to provide AI-based spatial biology analysis
Combining Lunaphore's Comet hyperplex staining and imaging platform, a fully automated sequential immunofluorescence (seqIF) instrument, with Nucleai's Atom artificial-intelligence (AI) spatial biology platform will enable the companies to generate new insights from tissue biopsies and provide labs with an integrated end-to-end spatial biology workflow.
September 8, 2022
2022 09 09 16 29 7140 Computer Head 400
BD, Labcorp to develop flow cytometry CDx
Specifically, the agreement creates a framework for BD and Labcorp Drug Development to collaborate on flow cytometry-based CDx opportunities with pharmaceutical partners.
August 8, 2022
2022 04 05 16 58 0661 Drug Discovery Development Analysis 400
Nucleai, Ultivue to partner on AI-based drug development platform
Under a comarketing agreement, the firms will integrate Nucleai's AI spatial models with Ultivue's imaging technology with the aim of speeding drug development.
June 5, 2022
2021 08 18 23 12 2135 Computer Ai Artificial Illustration 400
Stilla and Promega sign comarketing agreement
The companies have combined Promega's Maxwell liquid biopsy system and Stilla's naica system, a six-color multiplexing digital PCR platform. The pairing enables an optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research, and drug discovery, according to the vendors.
April 7, 2022
2020 04 14 22 00 7772 Business Men Handshake 400
PathAI, GSK partner to accelerate research, drug development
Under the agreement, GSK will gain access to PathAI's technologies in digital pathology, including its artificial intelligence-based measurement of NASH (AIM-NASH) tool, which provides AI-based NASH scoring.
April 4, 2022
2022 04 05 16 58 0661 Drug Discovery Development Analysis 400
Most Popular
Quest launches long-COVID testing panels for consumers
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
LumiraDx Q4 revenues drop 65% on lower COVID-19 testing
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
More in Drug Discovery and Development
Precision Medicine Institute to host show on AI and diagnostics
Attendees will see how AI developed by biotech companies are used in daily applications that support patient care, as well as drug discovery, targeting, and screening. The event will showcase the latest developments and trends in AI.
January 24, 2022
2020 03 11 18 43 2074 Artificial Intelligence Ai Suit 400
C2N Diagnostics debuts blood test to ID Alzheimer's disease
Samples from PrecivityAD are sent to the company's lab in St. Louis. Development of the test was supported by $2.8 million in funding from the Alzheimer's Drug Discovery Foundation over the past decade.
October 29, 2020
2019 07 15 19 08 6013 Amyloid Plaque Alzheimer 400
Scipher, Galapagos partner to develop IBD treatments
The two companies will jointly validate multiple IBD targets discovered by Scipher. The partnership will leverage the precision medicine firm's proprietary, artificial intelligence (AI)-driven Network Medicine Platform and molecular patient data.
August 12, 2020
2019 09 23 17 18 0797 Colon Intestine 400
Illumina Accelerator announces new genomics startups
Of the seven companies, three will mark the inaugural funding cycle of Illumina Accelerator Cambridge, U.K., while four other firms will join as part of the eleventh funding cycle in the San Francisco Bay Area, according to Illumina.
June 22, 2020
2020 04 14 19 46 7555 Business Deal Corporate 400
Twist Bioscience, Sophia Genetics partner on NGS, DNA analysis
South San Francisco, CA-based Twist has developed a DNA synthesis platform that involves manufacturing synthetic DNA for use in NGS preparation and the development of antibody libraries that inform drug discovery. Sophia Genetics, which has offices in the U.S., Switzerland, and France, has developed an AI-powered platform for DNA analysis.
February 25, 2020
2019 04 24 18 42 4242 Dna Blue 400
Fusion Genomics secures $1M U.S. to study respiratory infections panel
The Consortium Québécois sur la Découverte du Medicament (CQDM) is a Montreal-based biomedical research consortium that funds new technologies with potential value in facilitating drug discovery and development. The organization noted that since it was founded in 2008, it has raised more than $118 million Canadian ($90 million U.S.) through Canadian government programs and a wide range of pharmaceutical industry partners, including Merck, Pfizer, AstraZeneca, and Eli Lilly.
January 9, 2020
2019 12 06 22 21 9302 Lung Virus Bacteria 400
Page 1 of 2
Next Page